influenza vaccine (Sanofi)

Fluzone Intradermal is an inactivated influenza vaccine developed by Sanofi Pasteur that utilizes a specialized microinjection system (BD Soluvia) for delivery into the dermal layer of the skin. The dermis contains a high concentration of antigen-presenting cells, such as dendritic cells, which allows the vaccine to elicit an immune response comparable to standard intramuscular vaccines using a significantly smaller volume (0.1 mL) and a lower dose of antigen. Originally approved as a trivalent formulation (containing two influenza A strains and one influenza B strain), it was later updated to a quadrivalent version. The vaccine was indicated for adults aged 18 through 64 years. Sanofi discontinued the distribution of the intradermal formulation in the United States in 2018, shifting focus to other influenza vaccine products such as Fluzone High-Dose and Fluzone Quadrivalent.

Brand names

Fluzone IntradermalFluzone Intradermal QuadrivalentIntanzaIDflu

Other names

trivalent inactivated influenza vaccinequadrivalent inactivated influenza vaccineTIV-IDQIV-IDinfluenza virus vaccine